Multiparametric hippocampal signatures for early diagnosis of Alzheimer's disease using 18F-FDG PET/MRI Radiomics
Zhigeng Chen
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorSheng Bi
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorYi Shan
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorBixiao Cui
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorHongwei Yang
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorZhigang Qi
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorZhilian Zhao
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorYing Han
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorCorresponding Author
Shaozhen Yan
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Correspondence
Shaozhen Yan, Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Xicheng District, Beijing 100053, China.
Email: [email protected]
Search for more papers by this authorJie Lu
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorZhigeng Chen
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorSheng Bi
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorYi Shan
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorBixiao Cui
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorHongwei Yang
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorZhigang Qi
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorZhilian Zhao
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorYing Han
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorCorresponding Author
Shaozhen Yan
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Correspondence
Shaozhen Yan, Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Xicheng District, Beijing 100053, China.
Email: [email protected]
Search for more papers by this authorJie Lu
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China
Search for more papers by this authorThe first two authors contributed equally to the work.
Abstract
Purpose
This study aimed to explore the utility of hippocampal radiomics using multiparametric simultaneous positron emission tomography (PET)/magnetic resonance imaging (MRI) for early diagnosis of Alzheimer's disease (AD).
Methods
A total of 53 healthy control (HC) participants, 55 patients with amnestic mild cognitive impairment (aMCI), and 51 patients with AD were included in this study. All participants accepted simultaneous PET/MRI scans, including 18F-fluorodeoxyglucose (18F-FDG) PET, 3D arterial spin labeling (ASL), and high-resolution T1-weighted imaging (3D T1WI). Radiomics features were extracted from the hippocampus region on those three modal images. Logistic regression models were trained to classify AD and HC, AD and aMCI, aMCI and HC respectively. The diagnostic performance and radiomics score (Rad-Score) of logistic regression models were evaluated from 5-fold cross-validation.
Results
The hippocampal radiomics features demonstrated favorable diagnostic performance, with the multimodal classifier outperforming the single-modal classifier in the binary classification of HC, aMCI, and AD. Using the multimodal classifier, we achieved an area under the receiver operating characteristic curve (AUC) of 0.98 and accuracy of 96.7% for classifying AD from HC, and an AUC of 0.86 and accuracy of 80.6% for classifying aMCI from HC. The value of Rad-Score differed significantly between the AD and HC (p < 0.001), aMCI and HC (p < 0.001) groups. Decision curve analysis showed superior clinical benefits of multimodal classifiers compared to neuropsychological tests.
Conclusion
Multiparametric hippocampal radiomics using PET/MRI aids in the identification of early AD, and may provide a potential biomarker for clinical applications.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflicts of interest.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| cns14539-sup-0001-DataS1.docxWord 2007 document , 37.6 MB |
Data S1. |
| cns14539-sup-0002-DataS2.docxWord 2007 document , 8.5 MB |
Data S2. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 12023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023; 19(4): 1598-1695. doi:10.1002/alz.13016
- 2Gauthier S, Rosa-Neto P, Morais J, Webster C. World Alzheimer Report 2021: Journey through the Diagnosis of Dementia. Alzheimer's Disease International; 2021. Accessed September 21, 2021. https://www.alzint.org/u/World-Alzheimer-Report-2021.pdf
- 3Schmidtke K, Hermeneit S. High rate of conversion to Alzheimer's disease in a cohort of amnestic MCI patients. Int Psychogeriatr. 2008; 20(1): 96-108. doi:10.1017/s1041610207005509
- 4Yeung MK, Chau AK, Chiu JY, Shek JT, Leung JP, Wong TC. Differential and subtype-specific neuroimaging abnormalities in amnestic and nonamnestic mild cognitive impairment: a systematic review and meta-analysis. Ageing Res Rev. 2022; 80:101675. doi:10.1016/j.arr.2022.101675
- 5Burns DK, Alexander RC, Welsh-Bohmer KA, et al. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021; 20(7): 537-547. doi:10.1016/s1474-4422(21)00043-0
- 6Matthews DC, Mao X, Dowd K, et al. Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer's disease. Brain. 2021; 144(12): 3742-3755. doi:10.1093/brain/awab222
- 7Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021; 7(1):e12179. doi:10.1002/trc2.12179
- 8Brody M, Agronin M, Herskowitz BJ, et al. Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease. Alzheimers Dement. 2023; 19(1): 261-273. doi:10.1002/alz.12651
- 9Colliot O, Chételat G, Chupin M, et al. Discrimination between Alzheimer disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus. Radiology. 2008; 248(1): 194-201. doi:10.1148/radiol.2481070876
- 10Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case–control study. Lancet Neurol. 2012; 11(10): 868-877. doi:10.1016/s1474-4422(12)70200-4
- 11Szamosi A, Levy-Gigi E, Kelemen O, Kéri S. The hippocampus plays a role in the recognition of visual scenes presented at behaviorally relevant points in time: evidence from amnestic mild cognitive impairment (aMCI) and healthy controls. Cortex. 2013; 49(7): 1892-1900. doi:10.1016/j.cortex.2012.11.001
- 12Yan S, Zheng C, Cui B, et al. Multiparametric imaging hippocampal neurodegeneration and functional connectivity with simultaneous PET/MRI in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2020; 47(10): 2440-2452. doi:10.1007/s00259-020-04752-8
- 13Wang Z, Das SR, Xie SX, Arnold SE, Detre JA, Wolk DA. Arterial spin labeled MRI in prodromal Alzheimer's disease: a multi-site study. Neuroimage Clin. 2013; 2: 630-636. doi:10.1016/j.nicl.2013.04.014
- 14Khosravi M, Peter J, Wintering NA, et al. 18F-FDG is a superior indicator of cognitive performance compared to 18F-Florbetapir in Alzheimer's disease and mild cognitive impairment evaluation: a global quantitative analysis. J Alzheimers Dis. 2019; 70(4): 1197-1207. doi:10.3233/jad-190220
- 15Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002; 159(5): 738-745. doi:10.1176/appi.ajp.159.5.738
- 16Choi EJ, Son YD, Noh Y, Lee H, Kim YB, Park KH. Glucose Hypometabolism in hippocampal subdivisions in Alzheimer's disease: a pilot study using high-resolution 18F-FDG PET and 7.0-T MRI. J Clin Neurol. 2018; 14(2): 158-164. doi:10.3988/jcn.2018.14.2.158
- 17Chen Y, Wolk DA, Reddin JS, et al. Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology. 2011; 77(22): 1977-1985. doi:10.1212/WNL.0b013e31823a0ef7
- 18Feng F, Wang P, Zhao K, et al. Radiomic features of hippocampal subregions in Alzheimer's disease and amnestic mild cognitive impairment. Front Aging Neurosci. 2018; 10: 290. doi:10.3389/fnagi.2018.00290
- 19Zhao K, Ding Y, Han Y, et al. Independent and reproducible hippocampal radiomic biomarkers for multisite Alzheimer's disease: diagnosis, longitudinal progress and biological basis. Sci Bull (Beijing). 2020; 65(13): 1103-1113. doi:10.1016/j.scib.2020.04.003
- 20Xie L, Das SR, Pilania A, et al. Task-enhanced arterial spin labeled perfusion MRI predicts longitudinal neurodegeneration in mild cognitive impairment. Hippocampus. 2019; 29(1): 26-36. doi:10.1002/hipo.23026
- 21McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984; 34(7): 939-944. doi:10.1212/wnl.34.7.939
- 22Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256(3): 183-194. doi:10.1111/j.1365-2796.2004.01388.x
- 23Alsop DC, Detre JA, Golay X, et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med. 2015; 73(1): 102-116. doi:10.1002/mrm.25197
- 24Li W, Zhao Z, Liu M, et al. Multimodal classification of Alzheimer's disease and amnestic mild cognitive impairment: integrated 18F-FDG PET and DTI study. J Alzheimers Dis. 2022; 85(3): 1063-1075. doi:10.3233/jad-215338
- 25Li Y, Ng YL, Paranjpe MD, et al. Tracer-specific reference tissues selection improves detection of (18)F-FDG, (18) F-florbetapir, and (18)F-flortaucipir PET SUVR changes in Alzheimer's disease. Hum Brain Mapp. 2022; 43(7): 2121-2133. doi:10.1002/hbm.25774
- 26Yan S, Zheng C, Paranjpe MD, et al. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals. Brain. 2021; 144(10): 3201-3211. doi:10.1093/brain/awab160
- 27Nakazawa T, Ohara T, Hirabayashi N, et al. Multiple-region grey matter atrophy as a predictor for the development of dementia in a community: the Hisayama study. J Neurol Neurosurg Psychiatry. 2022; 93(3): 263-271. doi:10.1136/jnnp-2021-326611
- 28Laforce R Jr, Tosun D, Ghosh P, et al. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. Neuroimage Clin. 2014; 4: 508-516. doi:10.1016/j.nicl.2014.03.005
- 29Riederer I, Bohn KP, Preibisch C, et al. Alzheimer disease and mild cognitive impairment: integrated pulsed arterial spin-labeling MRI and (18)F-FDG PET. Radiology. 2018; 288(1): 198-206. doi:10.1148/radiol.2018170575
- 30Dolui S, Li Z, Nasrallah IM, Detre JA, Wolk DA. Arterial spin labeling versus (18)F-FDG-PET to identify mild cognitive impairment. Neuroimage Clin. 2020; 25:102146. doi:10.1016/j.nicl.2019.102146
- 31van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023; 388(1): 9-21. doi:10.1056/NEJMoa2212948
- 32Walsh S, Merrick R, Richard E, Nurock S, Brayne C. Lecanemab for Alzheimer's disease. BMJ. 2022; 379:o3010. doi:10.1136/bmj.o3010
- 33Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021; 13(1): 80. doi:10.1186/s13195-021-00813-8
- 34Saberi-Karimian M, Khorasanchi Z, Ghazizadeh H, et al. Potential value and impact of data mining and machine learning in clinical diagnostics. Crit Rev Clin Lab Sci. 2021; 58(4): 275-296. doi:10.1080/10408363.2020.1857681
- 35Battista P, Salvatore C, Berlingeri M, Cerasa A, Castiglioni I. Artificial intelligence and neuropsychological measures: the case of Alzheimer's disease. Neurosci Biobehav Rev. 2020; 114: 211-228. doi:10.1016/j.neubiorev.2020.04.026
- 36Bron EE, Klein S, Reinke A, et al. Ten years of image analysis and machine learning competitions in dementia. NeuroImage. 2022; 253:119083. doi:10.1016/j.neuroimage.2022.119083
- 37Grueso S, Viejo-Sobera R. Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer's disease dementia: a systematic review. Alzheimers Res Ther. 2021; 13(1): 162. doi:10.1186/s13195-021-00900-w
- 38Li X, Qiu Y, Zhou J, Xie Z. Applications and challenges of machine learning methods in Alzheimer's disease multi-source data analysis. Curr Genomics. 2021; 22(8): 564-582. doi:10.2174/1389202923666211216163049
- 39Martí-Juan G, Sanroma-Guell G, Piella G. A survey on machine and statistical learning for longitudinal analysis of neuroimaging data in Alzheimer's disease. Comput Methods Prog Biomed. 2020; 189:105348. doi:10.1016/j.cmpb.2020.105348
- 40Kim J, Lee M, Lee MK, et al. Development of random Forest algorithm based prediction model of Alzheimer's disease using neurodegeneration pattern. Psychiatry Investig. 2021; 18(1): 69-79. doi:10.30773/pi.2020.0304
- 41Adler DH, Wisse LEM, Ittyerah R, et al. Characterizing the human hippocampus in aging and Alzheimer's disease using a computational atlas derived from ex vivo MRI and histology. Proc Natl Acad Sci U S A. 2018; 115(16): 4252-4257. doi:10.1073/pnas.1801093115
- 42Du Y, Zhang S, Fang Y, et al. Radiomic features of the hippocampus for diagnosing early-onset and late-onset Alzheimer's disease. Front Aging Neurosci. 2021; 13:789099. doi:10.3389/fnagi.2021.789099
- 43Alongi P, Laudicella R, Panasiti F, et al. Radiomics analysis of brain [(18)F]FDG PET/CT to predict Alzheimer's disease in patients with amyloid PET positivity: a preliminary report on the application of SPM cortical segmentation, Pyradiomics and machine-learning analysis. Diagnostics (Basel). 2022; 12(4):933. doi:10.3390/diagnostics12040933
